”Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed
Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose”
Lu-177-PSMA-I&T for low volume Metastatic Castration-Resistant Prostate Cancer 
My Dad's Metastatic Prostate Cancer Update
Thymoquinone (found in negella sativa and monarda fistulosa plants) may target some castration resistant and/or metastatic prostate cancers
Apalutamide for Metastatic Castration-Sensitive Prostate CancerIs this pointing to cancer becoming castrate resistant?
